Alembic Pharmaceuticals gained 1.1% to Rs 983.95 after the drug maker announced that its joint venture has received US drug regulator's tentative approval for efinaconazole topical solution.
Alembic Pharma on Thursday announced that its joint venture Aleor Dermaceuticals (Aleor) has received tentative approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for efinaconazole topical solution.Efinaconazole topical solution is used to treat fungal toenail infections (infections that may cause nail discoloration, splitting, or pain). Efinaconazole topical solution is in a class of medications called antifungals. The product has an estimated market size of $233 million for twelve months ending December 2020 according to IQVIA.
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Jublia Topical Solution of Bausch Health Americas, Inc. Aleor has settled the case with Bausch Health and will launch its generic as per the terms of settlement.
Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. It manufactures and markets generic pharmaceutical products all over the world. The drug maker reported 13.8% jump in consolidated net profit to Rs 259.20 crore on a 8.7% rise in net sales to Rs 1,314.33 crore in Q3 FY21 over Q3 FY20.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU